Bello-Chavolla OY, Rojas-Martinez R, Aguilar-Salinas CA, Hernández-Avila M. Epidemiology of diabetes mellitus in Mexico. Nutr Rev. 2017;75(suppl 1):4–12.

Article  PubMed  Google Scholar 

International Diabetes Federation. IDF diabetes atlas—10th edition. Brussels: International Diabetes Federation; 2021. Available at: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf.

Seiglie JA, Franco RR, Wirtz VJ, Meigs JB, Mendoza MA, Miranda JJ, et al. Regional and state-level patterns of type 2 diabetes prevalence in Mexico over the last three decades. Diabetes Res Clin Pract. 2021;177: 108927.

Article  PubMed  Google Scholar 

Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA, Moreno-Banda GL, Carnalla M, et al. Prevalence of prediabetes and diabetes in Mexico. Ensanut 2022. Salud Publica Mex. 2023;65:S163–8.

Article  Google Scholar 

Arredondo A, Orozco E, Duarte MB, Cuadra M, Recaman AL, Azar A. Trends and challenges in diabetes for middle-income countries: evidence from Mexico. Glob Public Health. 2019;14(2):227–40.

Article  PubMed  Google Scholar 

Alegre-Díaz J, Herrington W, López-Cervantes M, Gnatiuc L, Ramirez R, Hill M, et al. Diabetes and cause-specific mortality in Mexico City. N Engl J Med. 2016;375(20):1961–71.

Article  PubMed  PubMed Central  Google Scholar 

Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.

Article  CAS  PubMed  Google Scholar 

Weng W, Tian Y, Kong SX, Ganguly R, Hersloev M, Brett J, et al. The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States. Endocrinol Diabetes Metab. 2019;2: e00076.

Article  PubMed  PubMed Central  Google Scholar 

McGurnaghan S, Blackbourn LAK, Mocevic E, Haagen Panton U, McCrimmon RJ, Sattar N, et al. Cardiovascular disease prevalence and risk factor prevalence in type 2 diabetes: a contemporary analysis. Diabet Med. 2019;36:718–25.

Article  CAS  PubMed  Google Scholar 

Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17:83.

Article  PubMed  PubMed Central  Google Scholar 

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.

Article  CAS  PubMed  Google Scholar 

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.

Article  CAS  PubMed  Google Scholar 

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

Article  CAS  PubMed  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

Article  CAS  PubMed  Google Scholar 

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

Article  CAS  PubMed  Google Scholar 

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. on behalf of the American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140–57.

Article  CAS  PubMed  Google Scholar 

Mosenzon O, Alguwaihes A, Arenas Leon JL, Bayram F, Darmon P, Davis TME, et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021;20(1):154.

Article  CAS  PubMed Central  Google Scholar 

American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2020. Diabetes Care. 2020;43:S111-34.

Article  Google Scholar 

Hao R, Myroniuk T, McGuckin T, Manca D, Campbell-Scherer D, Lau D, Yeung RO. Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study. BMC Prim Care. 2022;23(1):124.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marasinghe DH, Butalia S, Garies S, Drummond N, Kim JW, Senior PA. Low Use of Guideline-recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: a Cross-sectional Study of Adults With Type 2 Diabetes. Can J Diabetes. 2022;46(5):487–94.

Article  PubMed  Google Scholar 

Schernthaner G, Shehadeh N, Ametov AS, Bazarova AV, Ebrahimi F, Fasching P, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19(1):185.

Article  PubMed  PubMed Central  Google Scholar 

Cebrián-Cuenca AM, Mata-Cases M, Franch-Nadal J, Mauricio D, Orozco-Beltrán D, Consuegra-Sánchez L. Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC/EASD: data from a large Mediterranean population. Eur J Prev Cardiol. 2022;28(18):e32–4.

Article  PubMed  Google Scholar 

Bautista-Arredondo S, Vargas-Flores A, Moreno-Aguilar LA, Colchero MA. Health services utilization in Mexico: the 2022 cascade of care. Salud Publica Mex. 2023;65(S15):S22.

Google Scholar 

González Block MA, Reyes Morales H, Cahuana Hurtado L, Baladrán A, Méndez E. World Health Organization. Regional Office for Europe, European Observatory on Health Systems and Policies (2020). Mexico: health system review. World Health Organization. Regional Office for Europe. Available from: https://apps.who.int/iris/handle/10665/334334.

Flores-Hernández S, Acosta-Ruiz O, Hernández-Serrato MI, Delgado-Rodríguez S, Reyes-Morales H. Quality of care in type 2 diabetes, progress and challenges from 2012 to 2018–19 for the Mexican health system. Salud Publica Mex. 2020;62:618–26.

Article  PubMed  Google Scholar 

Escamilla-Núñez MC, Castro-Porras L, Romero-Martínez M, Zárate-Rojas E, Rojas-Martínez R. Screening, previous diagnosis, and treatment of chronic non-communicable diseases in Mexican adults. Ensanut 2022. Salud Publica Mex. 2023;65:S153–62.

Google Scholar 

Basto-Abreu AC, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA, De la,. Cruz-Góngora VV, Rivera-Dommarco J, et al Prevalence of diabetes and glycemic control in Mexico: national results from 2018 and 2020. Salud Publica Mex. 2021;63(6):725–33.

Article  PubMed  Google Scholar 

Basto-Abreu A, Barrientos-Gutiérrez T, Rojas-Martínez R, Aguilar-Salinas CA, López-Olmedo N, De la Cruz-Góngora V, et al. Prevalence of diabetes and poor glycemic control in Mexico: results from Ensanut 2016. Salud Publica Mex. 2020;62(1):50–9.

Article  PubMed  Google Scholar 

Khunti K, Aroda VR. Coming Full Circle: prioritizing Early Glycemic Control to Reduce Microvascular and Macrovascular Complications in People With Type 2 Diabetes. Diabetes Care. 2022;45(4):766–8.

Article  PubMed  Google Scholar 

Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020;63(2):221–8.

Article  PubMed  Google Scholar 

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. on behalf of the American Diabetes Association. 6. Glycemic Targets: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46:S97–110.

Article  PubMed  Google Scholar 

Bello-Chavolla OY, Antonio-Villa NE, Fermín-Martínez CA, Fernández-Chirino L, Vargas-Vázquez A, Ramírez-García D, et al. Diabetes-related excess mortality in Mexico: a comparative analysis of national death registries between 2017–2019 and 2020. Diabetes Care. 2022;45(12):2957–66.

Article  PubMed  PubMed Central  Google Scholar 

Barquera S, Campos-Nonato I, Aguilar-Salinas C, Lopez-Ridaura R, Arredondo A, Rivera-Dommarco J. Diabetes in Mexico: cost and management of diabetes and its complications and challenges for health policy. Global Health. 2013;9:3.

Article  PubMed  PubMed Central  Google Scholar 

Rawshany A, RawshanyA Franzen S, Sattar N, Eliasson B, Svensson AM, et al. Risk factors, mortality and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–44.

Article  Google Scholar 

Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337.

Article  PubMed  Google Scholar 

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.

Article  PubMed  Google Scholar 

Jerkins T, McGill JB, Bell DSH. Heart Failure and Diabetes: Clinical significance and epidemiology of this two-way association. Diabetes Obes Metab. 2023. https://doi.org/10.1111/dom.15062.

Article  PubMed  Google Scholar 

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.

Article  CAS